Monoclonal Antibodies (MAs) Market Forecast Signals New Revenue Opportunities Through 2030
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Monoclonal Antibodies (MAs) Market Revenue Growth Supported By A CAGR Of 464.38% Through 2030
In recent years, the monoclonal antibodies (mAbs) market has experienced rapid expansion. Its value is projected to increase from $256.03 billion in 2025 to $288.78 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.8%. This historic growth has been driven by advancements in antibody engineering, a growing prevalence of cancer and autoimmune diseases, an expanding number of approved biologic therapies, enhanced infrastructure for infusion centers, and higher healthcare expenditure.
The market size for monoclonal antibodies (mAbs) is anticipated to experience swift expansion over the coming years, reaching $464.39 billion by 2030 with a compound annual growth rate (CAGR) of 12.6%. This projected growth during the forecast period is driven by factors such as the expansion of targeted biologics pipelines, heightened use in managing chronic diseases, the proliferation of biosimilars, increased adoption of immunotherapy, and the growth of specialized clinics. Key trends likely to shape the forecast period include a growing preference for biologic-based therapies, greater application of monoclonal antibodies in oncology, the spread of infusion-based treatment facilities, enhanced adoption of humanized and fully human antibodies, and a stronger emphasis on long-term immunotherapy treatment plans.
Download A Free Sample Report For Comprehensive Market Insights:
Monoclonal Antibodies (MAs) Market Growth Momentum: Which Factors Are Influencing Demand?
The expanding availability of affordable biosimilar monoclonal antibodies is anticipated to fuel growth within the monoclonal antibody sector. These biosimilars are pharmaceuticals crafted to closely resemble an already authorized biological drug. Their growing acceptance is driven by increased patient demand for cost-effective biologic treatments, the expiration of patents on key branded monoclonal antibodies, and supportive regulatory frameworks that promote biosimilar development and market entry. The broader use of economical biosimilar monoclonal antibodies benefits the monoclonal antibody field by enhancing treatment accessibility, lowering healthcare costs, and fostering competitive innovation among drug manufacturers. As an example, in February 2025, the World Health Organization, a United Nations agency headquartered in Switzerland that focuses on global public health, reported that biosimilars are roughly 60% less expensive than original biologic medicines, offering considerable cost reductions that can widen access to vital biologic therapies. Consequently, the growing presence of cost-effective biosimilar monoclonal antibodies is propelling the expansion of the monoclonal antibody market.
The rising frequency of chronic conditions is set to accelerate growth in the monoclonal antibodies (mAbs) market in the coming years. Chronic diseases are enduring health issues that often cannot be cured but can be managed through appropriate medical care and lifestyle adjustments. This increase in chronic illnesses is attributed to lifestyle shifts linked to economic progress and urbanization, resulting in poor dietary habits, reduced physical activity, higher obesity rates, and related metabolic hazards. Monoclonal antibodies (mAbs) are utilized in addressing numerous chronic diseases, especially those involving disrupted immune responses, severe inflammation, and precise molecular targets. For example, in July 2023, the Health Foundation, an independent health policy research and analysis organization based in the United Kingdom, indicated that the number of individuals in England living with a major illness is expected to rise by 37% by 2040—a rate nine times higher than the 4% growth projected for the working-age population aged 20 to 69. Thus, the persistent escalation in chronic disease prevalence will continue to drive advancement in the monoclonal antibodies (mAbs) market.
Monoclonal Antibodies (MAs) Market Segment Analysis Highlighting Growth Areas
The monoclonal antibodies (mas) market covered in this report is segmented –
1) By Source: Murine, Chimeric, Humanized, Human
2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications
3) By End Users: Hospitals, Private Clinics, Research Institute
Subsegments:
1) By Murine: Fully Murine MAbs, Murine-Derived MAbs
2) By Chimeric: Chimeric MAbs With Murine Variable Regions, Chimeric MAbs With Human Constant Regions
3) By Humanized: Humanized MAbs With Minor Murine Components, Fully Humanized MAbs
4) By Human: Fully Human MAbs, Engineered Human MAbs
Monoclonal Antibodies (MAs) Market Trends Reshaping Industry Growth
Major players in the monoclonal antibodies market are rolling out cutting-edge technologies like RenMice to secure a competitive advantage. This platform significantly aids in advancing a range of antibody-based therapeutics, which include fully human monoclonal antibodies, bispecific antibodies, bispecific antibody-drug conjugates (BsADCs), nanobodies, fully human T-cell receptors (TCRs), and TCR-mimic antibodies. For example, in September 2023, Biocytogen Pharmaceuticals, a China-based global biotech firm dedicated to accelerating drug research and development through innovative technologies, unveiled the RenMice series. This collection features a range of independently developed fully human antibody mice and TCR mice, all protected by proprietary intellectual property rights.
Monoclonal Antibodies (MAs) Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the monoclonal antibodies (mas) market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Amgen Inc., Novartis International AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Sanofi S.A., Abbott Laboratories, Daiichi Sankyo Company Ltd., Seattle Genetics Inc., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Inc., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Biopharma Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals plc, Jiangsu Hengrui Medicine Co. Ltd., Piramal Enterprises Ltd., CD BioSciences Inc., Creative Biolabs Inc., Advanced ChemTech Inc., Tonbo Biosciences Inc., GlaxoSmithKline plc
Access The Complete Monoclonal Antibodies (MAs) Market Report:
Monoclonal Antibodies (MAs) Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the monoclonal antibodies (MAbS) market in 2025. The regions covered in the monoclonal antibodies (mas) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
